Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia

Annals of General Psychiatry

Volumn 15, Issue 1, 2016, Pages

  Yoshimura, Reiji ^a   Hori, Hikaru ^a   Katsuki, Asuka ^a   Atake, Kiyokazu ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 Methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Chronic schizophrenia; Positive and negative symptoms score

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; PRO BRAIN DERIVED NEUROTROPHIC FACTOR; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZOTEPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ELECTROCHEMICAL DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

EID: 84954214642     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-015-0084-9     Document Type: Article

References (21)

1. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol. 2000;15:175-80.
2. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry. 2010;11:256-61.
3. Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:913-22.
4. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-72.
5. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433-49.
6. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64:341-57.
7. Jiang C, Salton SR. The role of neurotrophins in major depressive disorder. Trens Neurosci. 2013;4:46-58.
8. Yoshida T, Ishikawa M, Niitsu T, et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One. 2012;7:e42676.
9. Zhou L, Xiong J, Lim Y. Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord. 2013;150:776-84.
10. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4:299-309.
11. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2006;6:603-14.
12. Barker PA. Whither proBDNF? Nat Neurosci. 2009;12:105-6.
13. Goto N, Yoshimura R, Kakeda S, Moriya J, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Hori H, Ueda N, Korogi Y, Nakamura J. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum Psychopharmacol. 2009;24:639-45.
14. Yoshimura R, Kishi T, Hori H, Atake K, Katsuki A, Nakano-Umene W, Ikenouchi-Sugita A, Iwata N, Nakamura J. Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder. Ann Gen Psychiatry. 2014;13:19.
15. Breier A, Elman I, Goldstein DS. Norepinephrine and schizophrenia: a new hypothesis for antipsychotic drug action. Adv Pharmacol. 1998;42:785-8.
16. See RE, Fido AA, Maurice M, Ibrahim MM, Salama GM. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry. 1999;45:1653-6.
17. Brown AS, Gewirtz G, Harkavy-Friedman J, Cooper T, Brébion G, Amador XF, Malaspina D, Gorman JM. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology. 1997;17:317-25.
18. Chen MJ, Nguyen TV, Pike CJ, Russo-Neustadt AA. Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal. 2007;19:114-28.
19. Juric DM, Miklic S, Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res. 2006;1103:54-62.
20. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, Nakano Y, Shinkai K, Mitoma M, Ohta M, Shinkai T, Nakamura J. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1072-7.
21. Yamamoto H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37-41.